Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid Tumors

Loading news article.

Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid Tumors | WAPE

Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid Tumors

Article summary

Related companies

Comments —